Discovery of highly potent, selective, and brain-penetrable leucine-rich repeat kinase 2 (LRRK2) small molecule inhibitors.

There is a high demand for potent, selective, and brain-penetrant small molecule inhibitors of leucine-rich repeat kinase 2 (LRRK2) to test whether inhibition of LRRK2 kinase activity is a potentially viable treatment option for Parkinson's disease patients. Herein we disclose the use of property and structure-based drug design for the optimization of highly ligand efficient aminopyrimidine lead compounds. High throughput in vivo rodent cassette pharmacokinetic studies enabled rapid validation of in vitro-in vivo correlations. Guided by this data, optimal design parameters were established. Effective incorporation of these guidelines into our molecular design process resulted in the discovery of small molecule inhibitors such as GNE-7915 (18) and 19, which possess an ideal balance of LRRK2 cellular potency, broad kinase selectivity, metabolic stability, and brain penetration across multiple species. Advancement of GNE-7915 into rodent and higher species toxicity studies enabled risk assessment for early development.

[1]  T. Dawson,et al.  Leucine-rich repeat kinase 2 (LRRK2) as a potential therapeutic target in Parkinson's disease. , 2012, Trends in pharmacological sciences.

[2]  Xianming Deng,et al.  Brain Penetrant LRRK2 Inhibitor. , 2012, ACS medicinal chemistry letters.

[3]  Jason Drummond,et al.  Discovery of selective LRRK2 inhibitors guided by computational analysis and molecular modeling. , 2012, Journal of medicinal chemistry.

[4]  Francesca Milletti,et al.  Targeted kinase selectivity from kinase profiling data. , 2012, ACS medicinal chemistry letters.

[5]  Xingrong Liu,et al.  Use of the Cassette-Dosing Approach to Assess Brain Penetration in Drug Discovery , 2012, Drug Metabolism and Disposition.

[6]  Jürgen Bajorath,et al.  MMP-Cliffs: Systematic Identification of Activity Cliffs on the Basis of Matched Molecular Pairs , 2012, J. Chem. Inf. Model..

[7]  S. Hitchcock,et al.  Structural modifications that alter the P-glycoprotein efflux properties of compounds. , 2012, Journal of medicinal chemistry.

[8]  B. Schmidt,et al.  Small molecule kinase inhibitors for LRRK2 and their application to Parkinson's disease models. , 2012, ACS chemical neuroscience.

[9]  Xianming Deng,et al.  Characterization of TAE684 as a potent LRRK2 kinase inhibitor. , 2012, Bioorganic & medicinal chemistry letters.

[10]  M. Cookson,et al.  Is inhibition of kinase activity the only therapeutic strategy for LRRK2-associated Parkinson's disease? , 2012, BMC Medicine.

[11]  K. Müller.  The power of MMPA and a teaching lesson in medicinal chemistry. , 2012, Journal of medicinal chemistry.

[12]  Jürgen Bajorath,et al.  Exploring activity cliffs in medicinal chemistry. , 2012, Journal of medicinal chemistry.

[13]  Akos Tarcsay,et al.  Impact of lipophilic efficiency on compound quality. , 2012, Journal of medicinal chemistry.

[14]  C. Manzoni,et al.  LRRK2 and Human Disease: A Complicated Question or a Question of Complexes? , 2012, Science Signaling.

[15]  J. Sanders,et al.  Leucine-Rich Repeat Kinase 2 (LRRK2) Cellular Biology: A Review of Recent Advances in Identifying Physiological Substrates and Cellular Functions , 2011, Journal of neurogenetics.

[16]  G. Drewes,et al.  Chemoproteomics-based design of potent LRRK2-selective lead compounds that attenuate Parkinson's disease-related toxicity in human neurons. , 2011, ACS chemical biology.

[17]  Daniel J. Warner,et al.  Matched molecular pairs as a medicinal chemistry tool. , 2011, Journal of medicinal chemistry.

[18]  T. Dawson,et al.  Inhibitors of LRRK2 kinase attenuate neurodegeneration and Parkinson-like phenotypes in Caenorhabditis elegans and Drosophila Parkinson's disease models. , 2011, Human molecular genetics.

[19]  J. Bajorath,et al.  Chemical transformations that yield compounds with distinct activity profiles. , 2011, ACS medicinal chemistry letters.

[20]  N. Gray,et al.  Characterization of a selective inhibitor of the Parkinson’s disease kinase LRRK2 , 2011, Nature chemical biology.

[21]  Minoru Ishikawa,et al.  Improvement in aqueous solubility in small molecule drug discovery programs by disruption of molecular planarity and symmetry. , 2011, Journal of medicinal chemistry.

[22]  Mark R. Cookson,et al.  The role of leucine-rich repeat kinase 2 (LRRK2) in Parkinson's disease , 2010, Nature Reviews Neuroscience.

[23]  L. Petrucelli,et al.  Inhibitors of Leucine Rich Repeat Kinase 2 (LRRK2) Protect Against LRRK2-Models of Parkinson’s Disease , 2010, Nature Medicine.

[24]  D. Cleveland,et al.  A chemical tool box defines mitotic and interphase roles for Mps1 kinase , 2010, The Journal of cell biology.

[25]  M. Farrer,et al.  LRRK2 and Parkinson disease. , 2010, Archives of neurology.

[26]  Bo Wang,et al.  Structure, function, regulation and polymorphism and the clinical significance of human cytochrome P450 1A2 , 2010, Drug metabolism reviews.

[27]  P. Verhoest,et al.  Moving beyond rules: the development of a central nervous system multiparameter optimization (CNS MPO) approach to enable alignment of druglike properties. , 2010, ACS Chemical Neuroscience.

[28]  P. Verhoest,et al.  Defining desirable central nervous system drug space through the alignment of molecular properties, in vitro ADME, and safety attributes. , 2010, ACS chemical neuroscience.

[29]  Taebo Sim,et al.  Small Molecule Kinase Inhibitors Provide Insight into Mps1 Cell Cycle Function , 2010, Nature chemical biology.

[30]  J. Buxbaum,et al.  Enhanced Striatal Dopamine Transmission and Motor Performance with LRRK2 Overexpression in Mice Is Eliminated by Familial Parkinson's Disease Mutation G2019S , 2010, The Journal of Neuroscience.

[31]  Kenji Tabata,et al.  A Comparison of Pharmacokinetics between Humans and Monkeys , 2010, Drug Metabolism and Disposition.

[32]  Yusuke Nakamura,et al.  Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson's disease , 2009, Nature Genetics.

[33]  C. Humblet,et al.  Escape from flatland: increasing saturation as an approach to improving clinical success. , 2009, Journal of medicinal chemistry.

[34]  Tania Cernuschi.  Pricing of pneumococcal vaccines under advance market commitments , 2009, The Lancet.

[35]  Shu-Feng Zhou,et al.  Insights into the Substrate Specificity, Inhibitors, Regulation, and Polymorphisms and the Clinical Impact of Human Cytochrome P450 1A2 , 2009, The AAPS Journal.

[36]  Hans Bitter,et al.  Identification of a Kinase Profile that Predicts Chromosome Damage Induced by Small Molecule Kinase Inhibitors , 2009, PLoS Comput. Biol..

[37]  John Hardy,et al.  Parkinson's disease , 2009, The Lancet.

[38]  L. Hennig,et al.  Fluorine hydrogen short contacts and hydrogen bonds in substituted benzamides , 2009 .

[39]  Shu G. Chen,et al.  Leucine‐rich repeat kinase 2 (LRRK2): A key player in the pathogenesis of Parkinson's disease , 2009, Journal of neuroscience research.

[40]  György M. Keserü,et al.  The influence of lead discovery strategies on the properties of drug candidates , 2009, Nature Reviews Drug Discovery.

[41]  M. Cookson,et al.  Leucine-rich repeat kinase 2 mutations and Parkinson’s disease: three questions , 2009, ASN neuro.

[42]  P. Leeson,et al.  The influence of drug-like concepts on decision-making in medicinal chemistry , 2007, Nature Reviews Drug Discovery.

[43]  David R. Anderson,et al.  Pyrrolopyridine inhibitors of mitogen-activated protein kinase-activated protein kinase 2 (MK-2). , 2007, Journal of medicinal chemistry.

[44]  Peter G. Schultz,et al.  Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK , 2007, Proceedings of the National Academy of Sciences.

[45]  S. Hitchcock,et al.  Structure-brain exposure relationships. , 2006, Journal of medicinal chemistry.

[46]  J. Cianfrogna,et al.  Evaluation of Cerebrospinal Fluid Concentration and Plasma Free Concentration As a Surrogate Measurement for Brain Free Concentration , 2006, Drug Metabolism and Disposition.

[47]  David W. Miller,et al.  Kinase activity is required for the toxic effects of mutant LRRK2/dardarin , 2006, Neurobiology of Disease.

[48]  Matthew J. Farrer,et al.  LRRK2 in Parkinson's disease: protein domains and functional insights , 2006, Trends in Neurosciences.

[49]  C. Ross,et al.  Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[50]  L. Wodicka,et al.  A small molecule–kinase interaction map for clinical kinase inhibitors , 2005, Nature Biotechnology.

[51]  Thomas Meitinger,et al.  Mutations in LRRK2 Cause Autosomal-Dominant Parkinsonism with Pleomorphic Pathology , 2004, Neuron.

[52]  Andrew Lees,et al.  Cloning of the Gene Containing Mutations that Cause PARK8-Linked Parkinson's Disease , 2004, Neuron.

[53]  Amos Bairoch,et al.  Swiss-Prot: Juggling between evolution and stability , 2004, Briefings Bioinform..

[54]  Junmei Wang,et al.  How well does a restrained electrostatic potential (RESP) model perform in calculating conformational energies of organic and biological molecules? , 2000, J. Comput. Chem..

[55]  R. Porter,et al.  Functional characterization of agonists at recombinant human 5‐HT2A, 5‐HT2B and 5‐HT2C receptors in CHO‐K1 cells , 1999, British journal of pharmacology.

[56]  スティーヴン・トム,et al.  The novel compounds , 1998 .

[57]  J. Thompson,et al.  CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. , 1994, Nucleic acids research.

[58]  T. Winkler,et al.  Weitreichende Kopplung zwischen Protonen und Fluor in 2-Fluorbenzamiden , 1974 .

[59]  M. Silver.  The β-Deuterium Isotope Effect in E1 Eliminations1 , 1961 .

[60]  T. Dawson,et al.  Inhibitors of LRRK 2 kinase attenuate neurodegeneration and Parkinson-like phenotypes in Caenorhabditis elegans and Drosophila Parkinson ’ s disease models , 2011 .

[61]  B. Wong,et al.  Preclinical pharmacokinetics of MK-0974, an orally active calcitonin-gene related peptide (CGRP)-receptor antagonist, mechanism of dose dependency and species differences. , 2009, Xenobiotica; the fate of foreign compounds in biological systems.

[62]  Jiunn H. Lin,et al.  CSF as a surrogate for assessing CNS exposure: an industrial perspective. , 2008, Current drug metabolism.